

David A Harrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8947560/publications.pdf>

Version: 2024-02-01

68
papers

2,370
citations

218677

26
h-index

223800

46
g-index

70
all docs

70
docs citations

70
times ranked

3228
citing authors

#	ARTICLE	IF	CITATIONS
1	The unique features of SARS-CoV-2 transmission: Comparison with SARS-CoV, MERS-CoV and 2009 H1N1 pandemic influenza virus. <i>Reviews in Medical Virology</i> , 2021, 31, e2171.	8.3	64
2	Dengue virus-free defective interfering particles have potent and broad anti-dengue virus activity. <i>Communications Biology</i> , 2021, 4, 557.	4.4	9
3	Assessing the Binding of Venoms from Aquatic Elapids to the Nicotinic Acetylcholine Receptor Orthosteric Site of Different Prey Models. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7377.	4.1	12
4	Evolutionary Interpretations of Nicotinic Acetylcholine Receptor Targeting Venom Effects by a Clade of Asian Viperidae Snakes. <i>Neurotoxicity Research</i> , 2020, 38, 312-318.	2.7	19
5	Tat-Based Therapies as an Adjuvant for an HIV-1 Functional Cure. <i>Viruses</i> , 2020, 12, 415.	3.3	18
6	An Appetite for Destruction: Detecting Prey-Selective Binding of δ -Neurotoxins in the Venom of Afro-Asian Elapids. <i>Toxins</i> , 2020, 12, 205.	3.4	32
7	A Taxon-Specific and High-Throughput Method for Measuring Ligand Binding to Nicotinic Acetylcholine Receptors. <i>Toxins</i> , 2019, 11, 600.	3.4	29
8	Oxazole-Benzenesulfonamide Derivatives Inhibit HIV-1 Reverse Transcriptase Interaction with Cellular eEF1A and Reduce Viral Replication. <i>Journal of Virology</i> , 2019, 93, .	3.4	8
9	eEF1A demonstrates paralog specific effects on HIV-1 reverse transcription efficiency. <i>Virology</i> , 2019, 530, 65-74.	2.4	8
10	Strong <i>In Vivo</i> Inhibition of HIV-1 Replication by Nullbasic, a Tat Mutant. <i>MBio</i> , 2019, 10, .	4.1	11
11	HIV-1 Uncoating and Reverse Transcription Require eEF1A Binding to Surface-Exposed Acidic Residues of the Reverse Transcriptase Thumb Domain. <i>MBio</i> , 2018, 9, .	4.1	18
12	RNA glycosidase and other agents target Tat to inhibit HIV-1 transcription. <i>Biochemical Journal</i> , 2018, 475, 1059-1062.	3.7	0
13	Differential Effects of Strategies to Improve the Transduction Efficiency of Lentiviral Vector that Conveys an Anti-HIV Protein, Nullbasic, in Human T Cells. <i>Virologica Sinica</i> , 2018, 33, 142-152.	3.0	5
14	The eukaryotic translation elongation factor 1A regulation of actin stress fibers is important for infectious RSV production. <i>Virology Journal</i> , 2018, 15, 182.	3.4	10
15	Toward the α -unravelling of HIV: Host cell factors involved in HIV-1 core uncoating. <i>PLoS Pathogens</i> , 2018, 14, e1007270.	4.7	12
16	A mutant Tat protein inhibits infection of human cells by strains from diverse HIV-1 subtypes. <i>Virology Journal</i> , 2017, 14, 52.	3.4	10
17	Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein. <i>MBio</i> , 2016, 7, .	4.1	16
18	The protein arginine methyltransferase PRMT6 inhibits HIV-1 Tat nucleolar retention. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 254-262.	4.1	13

#	ARTICLE	IF	CITATIONS
19	Binding of the eukaryotic translation elongation factor 1A with the 5'UTR of HIV-1 genomic RNA is important for reverse transcription. <i>Virology Journal</i> , 2015, 12, 118.	3.4	9
20	Specific Interaction between eEF1A and HIV RT Is Critical for HIV-1 Reverse Transcription and a Potential Anti-HIV Target. <i>PLoS Pathogens</i> , 2015, 11, e1005289.	4.7	16
21	A Mutant Tat Protein Inhibits HIV-1 Reverse Transcription by Targeting the Reverse Transcription Complex. <i>Journal of Virology</i> , 2015, 89, 4827-4836.	3.4	16
22	Evaluation of Polycaprolactone Matrices for Sustained Vaginal Delivery of Nevirapine in the Prevention of Heterosexual HIV Transmission. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2107-2115.	3.3	3
23	A HIV-1 Tat mutant protein disrupts HIV-1 Rev function by targeting the DEAD-box RNA helicase DDX1. <i>Retrovirology</i> , 2014, 11, 121.	2.0	28
24	Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 88, 406-414.	4.3	7
25	The Eukaryotic Elongation Factor 1A Is Critical for Genome Replication of the Paramyxovirus Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2014, 9, e114447.	2.5	22
26	Overexpression of PRMT6 does not suppress HIV-1 Tat transactivation in cells naturally lacking PRMT6. <i>Virology Journal</i> , 2013, 10, 207.	3.4	11
27	Revisiting transdominant-negative proteins in HIV gene therapy. <i>Future Virology</i> , 2013, 8, 757-768.	1.8	3
28	The Unexpected Roles of Eukaryotic Translation Elongation Factors in RNA Virus Replication and Pathogenesis. <i>Microbiology and Molecular Biology Reviews</i> , 2013, 77, 253-266.	6.6	98
29	An Evaluation of Polycaprolactone Matrices for Vaginal Delivery of the Antiviral, Tenofovir, in Preventing Heterosexual Transmission of HIV. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3725-3735.	3.3	12
30	A Mutant Tat Protein Provides Strong Protection from HIV-1 Infection in Human CD4+T Cells. <i>Human Gene Therapy</i> , 2013, 24, 270-282.	2.7	19
31	Ivermectin is a specific inhibitor of importin β -mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. <i>Biochemical Journal</i> , 2012, 443, 851-856.	3.7	559
32	Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9587-9592.	7.1	49
33	Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. <i>Biotechnology and Applied Biochemistry</i> , 2012, 59, 353-366.	3.1	11
34	Nullbasic, a Potent Anti-HIV Tat Mutant, Induces CRM1-Dependent Disruption of HIV Rev Trafficking. <i>PLoS ONE</i> , 2012, 7, e51466.	2.5	25
35	HIV gene therapy that's not a SIN. <i>HIV Therapy</i> , 2010, 4, 395-398.	0.6	0
36	Strand Transfer and Elongation of HIV-1 Reverse Transcription Is Facilitated by Cell Factors In Vitro. <i>PLoS ONE</i> , 2010, 5, e13229.	2.5	20

#	ARTICLE	IF	CITATIONS
37	Potent Inhibition of HIV-1 Replication by a Tat Mutant. PLoS ONE, 2009, 4, e7769.	2.5	47
38	Arginine Methylation Increases the Stability of Human Immunodeficiency Virus Type 1 Tat. Journal of Virology, 2009, 83, 11694-11703.	3.4	42
39	Reverse Transcriptase and Cellular Factors: Regulators of HIV-1 Reverse Transcription. Viruses, 2009, 1, 873-894.	3.3	37
40	Maturation of the HIV reverse transcription complex: putting the jigsaw together. Reviews in Medical Virology, 2009, 19, 324-337.	8.3	45
41	Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells. Retrovirology, 2008, 5, 115.	2.0	9
42	Cell Factors Stimulate Human Immunodeficiency Virus Type 1 Reverse Transcription In Vitro. Journal of Virology, 2008, 82, 1425-1437.	3.4	37
43	HIV-1 Tat implicated as a key factor in viral spread. Future HIV Therapy, 2008, 2, 323-326.	0.4	1
44	SOCS1: a host factor required for HIV-1 Gag trafficking. Future HIV Therapy, 2008, 2, 247-251.	0.4	1
45	The HIV-1 Tat Protein Stimulates Reverse Transcription In Vitro. Current HIV Research, 2007, 5, 474-483.	0.5	26
46	HIV-1 Replication from After Cell Entry to the Nuclear Periphery. Current HIV Research, 2007, 5, 293-299.	0.5	25
47	Functional relevance of nonsynonymous mutations in the HIV-1 tat gene within an epidemiologically-linked transmission cohort. Virology Journal, 2007, 4, 107.	3.4	2
48	Isolated HIV-1 core is active for reverse transcription. Retrovirology, 2007, 4, 77.	2.0	30
49	Protein methylation is required to maintain optimal HIV-1 infectivity. Retrovirology, 2006, 3, 92.	2.0	29
50	HIV Type 1 Inhibition by Protein Kinase C Modulatory Compounds. AIDS Research and Human Retroviruses, 2006, 22, 854-864.	1.1	65
51	Will Diverse Tat Interactions Lead to Novel Antiretroviral Drug Targets?. Current Drug Targets, 2006, 7, 1595-1606.	2.1	14
52	SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication. Journal of Biological Chemistry, 2006, 281, 31348-31358.	3.4	20
53	SerpinB2 Is an Inducible Host Factor Involved in Enhancing HIV-1 Transcription and Replication. Journal of Biological Chemistry, 2006, 281, 31348-31358.	3.4	8
54	Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virology Journal, 2005, 2, 17.	3.4	54

#	ARTICLE	IF	CITATIONS
55	The first strand transfer reaction of HIV-1 reverse transcription is more efficient in infected cells than in cell-free natural endogenous reverse transcription reactions. <i>Journal of Clinical Virology</i> , 2003, 26, 229-238.	3.1	17
56	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. <i>Molecular and Cellular Biology</i> , 2003, 23, 6520-6532.	2.3	64
57	Human Immunodeficiency Virus Type 1 Protease Regulation of Tat Activity Is Essential for Efficient Reverse Transcription and Replication. <i>Journal of Virology</i> , 2003, 77, 9912-9921.	3.4	29
58	Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine Development. <i>Journal of Virology</i> , 2003, 77, 7796-7803.	3.4	45
59	Kunjin Virus Replicon Vaccine Vectors Induce Protective CD8 + T-Cell Immunity. <i>Journal of Virology</i> , 2002, 76, 3791-3799.	3.4	70
60	Mechanistic aspects of HIV-1 reverse transcription initiation. <i>Reviews in Medical Virology</i> , 2002, 12, 31-45.	8.3	28
61	Human Immunodeficiency Virus Type 1 Reverse Transcription Is Stimulated by Tat from Other Lentiviruses. <i>Virology</i> , 2002, 300, 226-235.	2.4	11
62	Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Target Distinct Phases of Early Reverse Transcription. <i>Journal of Virology</i> , 2001, 75, 3095-3104.	3.4	47
63	Gag-Pol Supplied in trans Is Efficiently Packaged and Supports Viral Function in Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2001, 75, 6835-6840.	3.4	27
64	The Human Immunodeficiency Virus Type 1 TAR RNA Upper Stem-Loop Plays Distinct Roles in Reverse Transcription and RNA Packaging. <i>Journal of Virology</i> , 2000, 74, 5639-5646.	3.4	54
65	Functional Domains of Tat Required for Efficient Human Immunodeficiency Virus Type 1 Reverse Transcription. <i>Journal of Virology</i> , 1999, 73, 2499-2508.	3.4	38
66	<i>Treponema pallidum</i> , Lipoproteins, and Synthetic Lipoprotein Analogues Induce Human Immunodeficiency Virus Type 1 Gene Expression in Monocytes via NF- κ B Activation. <i>Journal of Infectious Diseases</i> , 1998, 177, 941-950.	4.0	64
67	Tat is required for efficient HIV-1 reverse transcription. <i>EMBO Journal</i> , 1997, 16, 1224-1235.	7.8	141
68	Repeated B motifs in the human immunodeficiency virus type I long terminal repeat enhancer region do not exhibit cooperative factor binding.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988, 85, 9406-9410.	7.1	40